KMO and Alzheimer disease: QUIN, the KP metabolite downstream of the kynurenine monooxygenase (KMO) enzyme, co-localizes with NFTs, indicating that KMO inhibition may have a complex therapeutic effect against AD by promoting the production of the neuroprotective KP metabolites KYNA and 3-HAA while simultaneously reducing the production of QUIN and potentially impacting the formation of NFTs [39].